Robbie Marcus
Stock Analyst at JP Morgan
(3.87)
# 598
Out of 5,146 analysts
180
Total ratings
54.24%
Success rate
8.59%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Overweight | $415 → $340 | $248.12 | +37.03% | 5 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Neutral | $105 → $100 | $96.65 | +3.47% | 13 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $135 → $100 | $73.48 | +36.09% | 14 | Feb 5, 2026 | |
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $83.40 | +19.90% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $59.25 | +99.16% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $83.47 | -6.55% | 7 | Dec 5, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $23.00 | +73.91% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $45.98 | +13.09% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $8.81 | +2.16% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $99.85 | +0.15% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $17 | $18.95 | -10.29% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $73.16 | +2.52% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $11.59 | +12.17% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $18.60 | -13.98% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $14.72 | +8.70% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $7.65 | -8.50% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $79.23 | +51.46% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $20.73 | +73.66% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $384.03 | +15.88% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $506.17 | +33.35% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $8.75 | +48.57% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $31.19 | +28.25% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $84.03 | +7.10% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $22.32 | +124.01% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $2.04 | +292.16% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $338.67 | -26.18% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.01 | +16.47% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $114.76 | +2.82% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $135.90 | +14.79% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $120.89 | -66.91% | 2 | May 5, 2020 |
Insulet
Feb 19, 2026
Maintains: Overweight
Price Target: $415 → $340
Current: $248.12
Upside: +37.03%
Medtronic
Feb 18, 2026
Maintains: Neutral
Price Target: $105 → $100
Current: $96.65
Upside: +3.47%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $135 → $100
Current: $73.48
Upside: +36.09%
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $83.40
Upside: +19.90%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $59.25
Upside: +99.16%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $83.47
Upside: -6.55%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $23.00
Upside: +73.91%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $45.98
Upside: +13.09%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $8.81
Upside: +2.16%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $99.85
Upside: +0.15%
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $18.95
Upside: -10.29%
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $73.16
Upside: +2.52%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $11.59
Upside: +12.17%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $18.60
Upside: -13.98%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $14.72
Upside: +8.70%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $7.65
Upside: -8.50%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $79.23
Upside: +51.46%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $20.73
Upside: +73.66%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $384.03
Upside: +15.88%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $506.17
Upside: +33.35%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $8.75
Upside: +48.57%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $31.19
Upside: +28.25%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $84.03
Upside: +7.10%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $22.32
Upside: +124.01%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $2.04
Upside: +292.16%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $338.67
Upside: -26.18%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.01
Upside: +16.47%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $114.76
Upside: +2.82%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $135.90
Upside: +14.79%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $120.89
Upside: -66.91%